Navigation Links
Study uncovers enzyme's double life, critical role in cancer blood supply
Date:3/4/2013

Studied for decades for their essential role in making proteins within cells, several amino acids known as tRNA synthetases were recently found to have an unexpected and critical additional role in cancer metastasis in a study conducted collaboratively in the labs of Karen Lounsbury, Ph.D., University of Vermont professor of pharmacology, and Christopher Francklyn, Ph.D., UVM professor of biochemistry. The group determined that threonyl tRNA synthetase (TARS) leads a "double life," functioning as a critical factor regulating a pathway used by invasive cancers to induce angiogenesis the formation of new blood vessels and a new food supply to sustain their growth.

The teams' research was published online February 21, 2013 in Nature Scientific Reports.

According to Tamara Williams, Ph.D., first author on the study, a lecturer in nursing and postdoctoral fellow in pharmacology at UVM, cancerous tumors quickly outgrow their local blood supply. When they do, the cancer cells send out signals, TARS is secreted, and the angiogenesis process is initiated.

"In our study, we showed that TARS, once thought to only function in the housekeeping role of protein synthesis within cells, 'moonlights' as a secreted signaling agent in the endothelial cells that line vessels, in response to factors commonly produced by cancer cells," says Williams.

The study's in vivo model of angiogenesis was performed using a chick chorioallantoic membrane assay. This experiment utilizes the vascular membrane that surrounds a ten-day-old chicken embryo, which is removed from its shell. Williams and her research teammates placed small pieces of surgical sponges on the surface of the membrane and added compounds, including TARS, to the sponges. The researchers took images of the sponges and surrounding tissues every 24 hours for three days and then analyzed the images to assess the impact of the compounds on local blood vessel development around the sponge. Their test determined whether the compound was angiogenic (creates new blood vessels), had no effect, or was angiostatic (inhibits blood vessel development). Using this assay, the group was able to demonstrate that TARS prompts angiogenesis by increasing the directional movement, or migration, of vessel cells towards the cancer cell signals. The group's research also showed that a potent inhibitor of TARS activity called inhibitor BC194 blocked its induction of angiogenesis.

"The implications of these novel and surprising findings are substantial for the cancer research community and include potential opportunities to develop new, early, and sensitive diagnostics," Williams says.

"Commercially, compounds that reduce TARS could be used to stop angiogenesis in cancer, compounds that increase TARS could promote angiogenesis, and a laboratory blood test for TARS could serve as a diagnostic for progression in certain cancers," says Kerry Swift, M.S., technology licensing officer in the UVM Office of Technology Commercialization.

Williams adds that the anti-angiogenic activity of the potent inhibitor of TARS paves the way for new therapeutics to block tumor growth and metastasis by stopping TARS-induced angiogenesis.

"These types of therapeutics could be used in combination with other treatments that target and kill cancer cells as part of a personalized cancer medicine approach to treat patients with greater success," she says.

On April 22, 2013, Francklyn will present a poster session on this research, titled "Mode of Action of Bioactive Natural Products," at the annual American Society for Biochemistry and Molecular Biology meeting in Boston, Mass. Lounsbury will present the project at the American Association for Cancer Research meeting, which takes place April 6 to 10, 2013 in Washington, D.C.


'/>"/>

Contact: Jennifer Nachbur
jennifer.nachbur@uvm.edu
802-656-7875
University of Vermont
Source:Eurekalert

Related biology news :

1. Study maps human metabolism in health and disease
2. Volcanic aerosols, not pollutants, tamped down recent Earth warming, says CU-Boulder study
3. Study provides insights into plant evolution
4. New study reveals how sensitive US East Coast regions may be to ocean acidification
5. CETS offers new method to help simplify the study of brain pathologies
6. New study could explain why some people get zits and others dont
7. Global tipping point not backed by science: Study
8. Study led by NUS researchers proves the existence of 3 overstretched DNA structures
9. Wayne State study shows airborne dust in urban areas impacts lead levels in children
10. Georgia Physicians Study Published in The Journal of Urology
11. New study shows continued decline in the last remaining stronghold for leatherback sea turtles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2018)... ... August 02, 2018 , ... RxS LLC (“RxS”), a ... today announced that Mark Jara, principal of the organization, has been named to ... industry. Individuals named to PharmaVOICE 100 are leaders who drive the industry forward ...
(Date:8/1/2018)... ... August 01, 2018 , ... Clinical ... LPN’s, MA's and Administrative staff. , This full day course is an interactive ... course will expose your staff to regenerative medicine procedures and processing techniques, and ...
(Date:7/31/2018)... ... 31, 2018 , ... Lifecycle Biotechnologies, a leading life science ... this role, Mr. Muzek will lead the company-wide industrial strategic business development efforts ... , With over 20 years in business development, Mr. Muzek previously served as ...
Breaking Biology News(10 mins):
(Date:8/17/2018)... ... August 17, 2018 , ... VANCOUVER, British Columbia, Canada, August ... pleased to announce the release of the Russian translation of Best Practices: Recommendations ... 2018, is a practice-changing publication aimed at advancing the science of biobanking to ...
(Date:8/14/2018)... , ... August 14, 2018 , ... ... impetus at the 11th Congress of the Chinese Association of Orthopaedic Surgeons (CAOS) ... Fule Science & Technology Development , Beijing, and Invibio Biomaterial Solutions ...
(Date:8/9/2018)... ... 2018 , ... ActX introduces GenoACT(sm), a Genetic Clinical Decision ... talented scientific team that includes geneticists, PharmD’s, genetic counselors, and physicians aided by ... medical impact of a patient’s genetic variants , 2. Educational information for clinicians, ...
(Date:8/9/2018)... ... 09, 2018 , ... MedEvolve, Inc. , a national ... software and services for physician practices, announced today the company’s bookings for second ... record quarters in Q2 and Q3 last year, the company has exceeded those ...
Breaking Biology Technology: